{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T03:13:06Z","timestamp":1675825986666},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,3,6]],"date-time":"2010-03-06T00:00:00Z","timestamp":1267833600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1007\/s10549-010-0806-2","type":"journal-article","created":{"date-parts":[[2010,3,5]],"date-time":"2010-03-05T05:47:16Z","timestamp":1267768036000},"page":"303-306","source":"Crossref","is-referenced-by-count":9,"title":["PALB2 mutations 1592delT and 229delT are not present in Korean breast cancer patients negative for BRCA1 and BRCA2 mutations"],"prefix":"10.1007","volume":"122","author":[{"given":"Jin Ho","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doo Ho","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae Yeon","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sei Hyun","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung Ho","family":"Son","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce G.","family":"Haffty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,3,6]]},"reference":[{"key":"806_CR1","volume-title":"Breast cancer facts & figures\u00a02009\u20132010","author":"American Cancer Society","year":"2009","unstructured":"American Cancer Society (2009) Breast cancer facts & figures\u00a02009\u20132010. American Cancer Society, Atlanta"},{"key":"806_CR2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","volume":"266","author":"Y Miki","year":"1994","unstructured":"Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66\u201371","journal-title":"Science"},{"key":"806_CR3","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/378789a0","volume":"378","author":"R Wooster","year":"1995","unstructured":"Wooster R, Bignell G, Lancaster J et al (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789\u2013792","journal-title":"Nature"},{"key":"806_CR4","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/jnci\/91.11.943","volume":"91","author":"J Peto","year":"1999","unstructured":"Peto J, Collins N, Barfoot R et al (1999) Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91:943\u2013949","journal-title":"J Natl Cancer Inst"},{"key":"806_CR5","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jama.279.12.915","volume":"279","author":"B Newman","year":"1998","unstructured":"Newman B, Mu H, Butler LM et al (1998) Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 279:915\u2013921","journal-title":"JAMA"},{"key":"806_CR6","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1056\/NEJMra012284","volume":"348","author":"R Wooster","year":"2003","unstructured":"Wooster R, Weber BL (2003) Breast and ovarian cancer. N Engl J Med 348:2339\u20132347","journal-title":"N Engl J Med"},{"key":"806_CR7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/ng853","volume":"31","author":"PDP Pharoah","year":"2002","unstructured":"Pharoah PDP, Antoniou A, Bobrow M et al (2002) Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 31:33\u201336","journal-title":"Nat Genet"},{"key":"806_CR8","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ng1947","volume":"39","author":"S Reid","year":"2007","unstructured":"Reid S, Schindler D, Hanenberg H et al (2007) Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 39:162\u2013164","journal-title":"Nat Genet"},{"key":"806_CR9","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nrg2159","volume":"8","author":"W Wang","year":"2007","unstructured":"Wang W (2007) Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 8:735\u2013748","journal-title":"Nat Rev Genet"},{"key":"806_CR10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/ng1942","volume":"39","author":"B Xia","year":"2007","unstructured":"Xia B, Dorsman JC, Ameziane N et al (2007) Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet 39:159\u2013161","journal-title":"Nat Genet"},{"key":"806_CR11","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.molcel.2006.05.022","volume":"22","author":"B Xia","year":"2006","unstructured":"Xia B, Sheng Q, Nakanishi K et al (2006) Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 22:719\u2013729","journal-title":"Mol Cell"},{"key":"806_CR12","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/ng1959","volume":"39","author":"N Rahman","year":"2007","unstructured":"Rahman N, Seal S, Thompson D et al (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39:165\u2013167","journal-title":"Nat Genet"},{"key":"806_CR13","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nature05609","volume":"446","author":"H Erkko","year":"2007","unstructured":"Erkko H, Xia B, Nikkil\u00e4 J et al (2007) A recurrent mutation in PALB2 in Finnish cancer families. Nature 446:316\u2013319","journal-title":"Nature"},{"key":"806_CR14","doi-asserted-by":"crossref","first-page":"R83","DOI":"10.1186\/bcr1828","volume":"9","author":"WD Foulkes","year":"2007","unstructured":"Foulkes WD, Ghadirian P, Akbari MR et al (2007) Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women. Breast Cancer Res 9:R83","journal-title":"Breast Cancer Res"},{"key":"806_CR15","doi-asserted-by":"crossref","first-page":"6788","DOI":"10.1073\/pnas.0701724104","volume":"104","author":"M Tischkowitz","year":"2007","unstructured":"Tischkowitz M, Xia B, Sabbaghian N et al (2007) Analysis of PALB2\/FANCN-associated breast cancer families. Proc Natl Acad Sci USA 104:6788\u20136793","journal-title":"Proc Natl Acad Sci USA"},{"key":"806_CR16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10549-008-0036-z","volume":"114","author":"A Cao","year":"2009","unstructured":"Cao A, Huang J, Hu Z et al (2009) The prevalence of PALB2 germline mutations in BRCA1\/BRCA2 negative Chinese women with early onset breast cancer or affected relatives. Breast Cancer Res Treat 114:457\u2013462","journal-title":"Breast Cancer Res Treat"},{"key":"806_CR17","doi-asserted-by":"crossref","unstructured":"Papi L, Putignano A, Congregati C et al (2009) A PALB2 germline mutation associated with hereditary breast cancer in Italy. Fam Cancer. doi: 10.1007\/s10689-009-9295-z","DOI":"10.1007\/s10689-009-9295-z"},{"key":"806_CR18","volume-title":"SEER cancer statistics review, 1975\u20132006","author":"M Horner","year":"2009","unstructured":"Horner M, Ries L, Krapcho M et al (2009) SEER cancer statistics review, 1975\u20132006. National Cancer Institute, Bethesda, MD"},{"key":"806_CR19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1001\/archsurg.141.2.155","volume":"141","author":"BH Son","year":"2006","unstructured":"Son BH, Kwak BS, Kim JK et al (2006) Changing patterns in the clinical characteristics of Korean patients with breast cancer during the last 15\u00a0years. Arch Surg 141:155\u2013160","journal-title":"Arch Surg"},{"key":"806_CR20","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/jso.21110","volume":"98","author":"SS Ko","year":"2008","unstructured":"Ko SS (2008) Chronological changing patterns of clinical characteristics of Korean breast cancer patients during 10\u00a0years (1996\u20132006) using nationwide breast cancer registration on-line program: biannual update. J Surg Oncol 98:318\u2013323","journal-title":"J Surg Oncol"},{"key":"806_CR21","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1200\/JCO.2004.04.179","volume":"22","author":"DH Choi","year":"2004","unstructured":"Choi DH, Lee MH, Bale AE et al (2004) Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients. J Clin Oncol 22:1638\u20131645","journal-title":"J Clin Oncol"},{"key":"806_CR22","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3346\/jkms.2004.19.2.269","volume":"19","author":"SH Ahn","year":"2004","unstructured":"Ahn SH, Hwang UK, Kwak BS et al (2004) Prevalence of BRCA1 and BRCA2 mutations in Korean breast cancer patients. J Korean Med Sci 19:269\u2013274","journal-title":"J Korean Med Sci"},{"key":"806_CR23","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s10549-007-9878-z","volume":"112","author":"DH Choi","year":"2008","unstructured":"Choi DH, Cho DY, Lee MH, Park HS, Ahn SH, Son BH, Haffty BruceG (2008) The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutations. Breast Cancer Res Treat 112:569\u2013573","journal-title":"Breast Cancer Res Treat"},{"key":"806_CR24","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10549-008-9945-0","volume":"113","author":"MJ Garc\u00eda","year":"2009","unstructured":"Garc\u00eda MJ, Fern\u00e1ndez V, Osorio A et al (2009) Analysis of FANCB and FANCN\/PALB2 fanconi anemia genes in BRCA1\/2-negative Spanish breast cancer families. Breast Cancer Res Treat 113:545\u2013551","journal-title":"Breast Cancer Res Treat"},{"key":"806_CR25","doi-asserted-by":"crossref","unstructured":"Sluiter M, Mew S, van Rensburg E (2009) PALB2 sequence variants in young South African breast cancer patients. Fam Cancer 8:347\u2013353","DOI":"10.1007\/s10689-009-9241-0"},{"key":"806_CR26","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1158\/1078-0432.CCR-08-0210","volume":"14","author":"H Erkko","year":"2008","unstructured":"Erkko H, Dowty JG, Nikkil\u00e4 J et al (2008) Penetrance analysis of the PALB2 c.1592delT founder mutation. Clin Cancer Res 14:4667\u20134671","journal-title":"Clin Cancer Res"},{"key":"806_CR27","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1158\/1078-0432.CCR-08-3128","volume":"15","author":"T Heikkinen","year":"2009","unstructured":"Heikkinen T, K\u00e4rkk\u00e4inen H, Aaltonen K et al (2009) The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype. Clin Cancer Res 15:3214\u20133222","journal-title":"Clin Cancer Res"},{"key":"806_CR28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1477-5751-7-5","volume":"7","author":"H Gunnarsson","year":"2008","unstructured":"Gunnarsson H, Arason A, Gillanders EM et al (2008) Evidence against PALB2 involvement in Icelandic breast cancer susceptibility. J Negat Results Biomed 7:5","journal-title":"J Negat Results Biomed"},{"key":"806_CR29","doi-asserted-by":"crossref","unstructured":"McInerney N, Miller N, Rowan A et al (2009) Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort. Breast Cancer Res Treat. doi: 10.1007\/s10549-009-0540-9","DOI":"10.1007\/s10549-009-0540-9"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-010-0806-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-010-0806-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-010-0806-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T16:32:29Z","timestamp":1559233949000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-010-0806-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,6]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["806"],"URL":"https:\/\/doi.org\/10.1007\/s10549-010-0806-2","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,6]]}}}